Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.

Original publication




Journal article


The Journal of rheumatology. Supplement

Publication Date





17 - 25


From the Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Royal National Hospital for Rheumatic Diseases, Bath, UK; University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Oxford, Oxford, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA; Department of Rheumatology, St. Vincents University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; VU Medical Centre, Amsterdam, the Netherlands; IQVIA, Duke University School of Medicine, Durham, North Carolina, USA; School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.